Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial

Jane Pei Chen Chang, Shih Sheng Chang, Hui Ting Yang, Hui Ting Chen, Yu Chuan Chien, Bo Yang, Huanxing Su, Kuan Pin Su

研究成果: 雜誌貢獻文章

3 引文 (Scopus)

摘要

Introduction: Cardiovascular diseases (CVDs) and major depressive disorder (MDD) will be the two most disabling diseases by 2030. Patients with CVDs comorbid depression had lower levels of total omega-3 polyunsaturated fatty acids (n-3 PUFAs), docosahexaenoic acid (DHA), and a higher omega-6 to omega-3 ratio. However, there have been limited studies on the effects n-3 PUFAs on MDD in patients with CVDs. Method: We have enrolled a total of 59 patients (64% males, mean age of 61.5 ± 9.0 years and mean education of 10.2 ± 4.2 years) with CVDs comorbid MDD. They were randomized into either receiving n-3 PUFAs (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA) or placebo for 12 weeks. We assessed depression symptom severity with Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI), as well as blood fatty acid levels, electrocardiogram and blood biochemistry, at the baseline and at the endpoint. Results: There were no differences between the n-3 PUFAs and placebo group in the changes of HAMD and BDI total scores, while PUFAs group had a greater reduction in HAMD Cognition subscale scores than the placebo group at week 8 (p < 0.05). Moreover, subgroup analyses found that the n-3 group had a greater reduction of HAMD Core subscale scores than the placebo group at the end of week 12 (p < 0.05) for the very severe DEP group (HAMD ≥ 23). Conclusion: Overall, n-3 PUFAs did not show a beneficial effect on depressive symptoms when compared with placebo. However, when stratified with depression severity, n-3 PUFAs supplementation improved core depression symptoms in the very severe MDD group. N-3 PUFAs supplementation may provide a treatment option for a subpopulation of patients with CVDs comorbid MDD.
原文英語
期刊Brain, Behavior, and Immunity
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

Major Depressive Disorder
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Cardiovascular Diseases
Randomized Controlled Trials
Depression
Placebos
Docosahexaenoic Acids
Equipment and Supplies
Eicosapentaenoic Acid
Biochemistry
Cognition
Electrocardiography
Fatty Acids
Education

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

引用此文

Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial. / Chang, Jane Pei Chen; Chang, Shih Sheng; Yang, Hui Ting; Chen, Hui Ting; Chien, Yu Chuan; Yang, Bo; Su, Huanxing; Su, Kuan Pin.

於: Brain, Behavior, and Immunity, 01.01.2019.

研究成果: 雜誌貢獻文章

Chang, Jane Pei Chen ; Chang, Shih Sheng ; Yang, Hui Ting ; Chen, Hui Ting ; Chien, Yu Chuan ; Yang, Bo ; Su, Huanxing ; Su, Kuan Pin. / Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial. 於: Brain, Behavior, and Immunity. 2019.
@article{7f6f8354d61a43aabc2de78758510d62,
title = "Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial",
abstract = "Introduction: Cardiovascular diseases (CVDs) and major depressive disorder (MDD) will be the two most disabling diseases by 2030. Patients with CVDs comorbid depression had lower levels of total omega-3 polyunsaturated fatty acids (n-3 PUFAs), docosahexaenoic acid (DHA), and a higher omega-6 to omega-3 ratio. However, there have been limited studies on the effects n-3 PUFAs on MDD in patients with CVDs. Method: We have enrolled a total of 59 patients (64{\%} males, mean age of 61.5 ± 9.0 years and mean education of 10.2 ± 4.2 years) with CVDs comorbid MDD. They were randomized into either receiving n-3 PUFAs (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA) or placebo for 12 weeks. We assessed depression symptom severity with Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI), as well as blood fatty acid levels, electrocardiogram and blood biochemistry, at the baseline and at the endpoint. Results: There were no differences between the n-3 PUFAs and placebo group in the changes of HAMD and BDI total scores, while PUFAs group had a greater reduction in HAMD Cognition subscale scores than the placebo group at week 8 (p < 0.05). Moreover, subgroup analyses found that the n-3 group had a greater reduction of HAMD Core subscale scores than the placebo group at the end of week 12 (p < 0.05) for the very severe DEP group (HAMD ≥ 23). Conclusion: Overall, n-3 PUFAs did not show a beneficial effect on depressive symptoms when compared with placebo. However, when stratified with depression severity, n-3 PUFAs supplementation improved core depression symptoms in the very severe MDD group. N-3 PUFAs supplementation may provide a treatment option for a subpopulation of patients with CVDs comorbid MDD.",
keywords = "Cardiovascular diseases, DHA, EPA, Major depressive disorder, Omega-3 fatty acid, PUFAs",
author = "Chang, {Jane Pei Chen} and Chang, {Shih Sheng} and Yang, {Hui Ting} and Chen, {Hui Ting} and Chien, {Yu Chuan} and Bo Yang and Huanxing Su and Su, {Kuan Pin}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbi.2019.03.012",
language = "English",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial

AU - Chang, Jane Pei Chen

AU - Chang, Shih Sheng

AU - Yang, Hui Ting

AU - Chen, Hui Ting

AU - Chien, Yu Chuan

AU - Yang, Bo

AU - Su, Huanxing

AU - Su, Kuan Pin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Cardiovascular diseases (CVDs) and major depressive disorder (MDD) will be the two most disabling diseases by 2030. Patients with CVDs comorbid depression had lower levels of total omega-3 polyunsaturated fatty acids (n-3 PUFAs), docosahexaenoic acid (DHA), and a higher omega-6 to omega-3 ratio. However, there have been limited studies on the effects n-3 PUFAs on MDD in patients with CVDs. Method: We have enrolled a total of 59 patients (64% males, mean age of 61.5 ± 9.0 years and mean education of 10.2 ± 4.2 years) with CVDs comorbid MDD. They were randomized into either receiving n-3 PUFAs (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA) or placebo for 12 weeks. We assessed depression symptom severity with Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI), as well as blood fatty acid levels, electrocardiogram and blood biochemistry, at the baseline and at the endpoint. Results: There were no differences between the n-3 PUFAs and placebo group in the changes of HAMD and BDI total scores, while PUFAs group had a greater reduction in HAMD Cognition subscale scores than the placebo group at week 8 (p < 0.05). Moreover, subgroup analyses found that the n-3 group had a greater reduction of HAMD Core subscale scores than the placebo group at the end of week 12 (p < 0.05) for the very severe DEP group (HAMD ≥ 23). Conclusion: Overall, n-3 PUFAs did not show a beneficial effect on depressive symptoms when compared with placebo. However, when stratified with depression severity, n-3 PUFAs supplementation improved core depression symptoms in the very severe MDD group. N-3 PUFAs supplementation may provide a treatment option for a subpopulation of patients with CVDs comorbid MDD.

AB - Introduction: Cardiovascular diseases (CVDs) and major depressive disorder (MDD) will be the two most disabling diseases by 2030. Patients with CVDs comorbid depression had lower levels of total omega-3 polyunsaturated fatty acids (n-3 PUFAs), docosahexaenoic acid (DHA), and a higher omega-6 to omega-3 ratio. However, there have been limited studies on the effects n-3 PUFAs on MDD in patients with CVDs. Method: We have enrolled a total of 59 patients (64% males, mean age of 61.5 ± 9.0 years and mean education of 10.2 ± 4.2 years) with CVDs comorbid MDD. They were randomized into either receiving n-3 PUFAs (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA) or placebo for 12 weeks. We assessed depression symptom severity with Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI), as well as blood fatty acid levels, electrocardiogram and blood biochemistry, at the baseline and at the endpoint. Results: There were no differences between the n-3 PUFAs and placebo group in the changes of HAMD and BDI total scores, while PUFAs group had a greater reduction in HAMD Cognition subscale scores than the placebo group at week 8 (p < 0.05). Moreover, subgroup analyses found that the n-3 group had a greater reduction of HAMD Core subscale scores than the placebo group at the end of week 12 (p < 0.05) for the very severe DEP group (HAMD ≥ 23). Conclusion: Overall, n-3 PUFAs did not show a beneficial effect on depressive symptoms when compared with placebo. However, when stratified with depression severity, n-3 PUFAs supplementation improved core depression symptoms in the very severe MDD group. N-3 PUFAs supplementation may provide a treatment option for a subpopulation of patients with CVDs comorbid MDD.

KW - Cardiovascular diseases

KW - DHA

KW - EPA

KW - Major depressive disorder

KW - Omega-3 fatty acid

KW - PUFAs

UR - http://www.scopus.com/inward/record.url?scp=85064265763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064265763&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2019.03.012

DO - 10.1016/j.bbi.2019.03.012

M3 - Article

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

ER -